BioMarin Pharmaceutical (NASDAQ:BMRN) Issues Quarterly Earnings Results, Beats Expectations By $0.31 EPS

BioMarin Pharmaceutical (NASDAQ:BMRN) announced its quarterly earnings results on Monday. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.31, FiscalAI reports. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the prior year, the firm earned $0.12 EPS. The firm’s quarterly revenue was up 32.0% compared to the same quarter last year.

Here are the key takeaways from BioMarin Pharmaceutical’s conference call:

• Third-quarter revenue rose 32% year over year to more than $1 billion, driven by broad-based demand across BioMarin’s portfolio. Metabolic conditions revenue increased 44%, while VOXZOGO patient counts grew 17% globally.
• GALAFOLD revenue increased 10% to $152 million and POMBILITI + OPFOLDA revenue rose 58% to $49 million, with patient counts up approximately 13% and 69%, respectively. Management expects Pompe revenue benefits from competitor supply constraints to build into 2027 and beyond, although the durability of those gains remains uncertain.
• BioMarin lowered 2026 guidance to revenue of $3.8 billion-$3.9 billion and non-GAAP diluted EPS of $2.80-$3.10. The revision reflects roughly $70 million of customer orders potentially moving from late 2026 into early 2027, along with disruption and liquidity pressures related to the Middle East conflict.
• VOXZOGO’s potential expansion into hypochondroplasia received a May 30, 2027 PDUFA date, creating a potential new growth opportunity in an estimated 14,000-child global market. Management expects VOXZOGO revenue to continue growing in 2027 despite competitive pressures and order-timing uncertainty.
• BioMarin added four pipeline programs in 2026, including BMN 450 for potentially subcutaneous, mutation-agnostic Fabry treatment and BMN 440 as a potential oral therapy for hypophosphatasia. Amicus integration is ahead of schedule, with management now expecting the deal to be accretive within nine months and tracking toward possible 2026 calendar-year accretion.

BioMarin Pharmaceutical Stock Down 1.8%

Shares of BioMarin Pharmaceutical stock opened at $57.44 on Tuesday. The business has a 50-day moving average price of $60.43 and a 200 day moving average price of $58.46. BioMarin Pharmaceutical has a fifty-two week low of $49.26 and a fifty-two week high of $70.98. The firm has a market cap of $11.12 billion, a P/E ratio of 33.33, a P/E/G ratio of 0.61 and a beta of 0.22. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Oppenheimer upped their target price on BioMarin Pharmaceutical from $95.00 to $97.00 and gave the stock an “outperform” rating in a research report on Friday, August 7th. Raymond James Financial upgraded BioMarin Pharmaceutical from an “outperform” rating to a “strong-buy” rating and set a $109.00 target price on the stock in a report on Monday, October 12th. Jefferies Financial Group boosted their price target on BioMarin Pharmaceutical from $104.00 to $105.00 and gave the stock a “buy” rating in a research report on Monday, August 31st. Barclays boosted their price target on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 14th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $86.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday, October 20th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, BioMarin Pharmaceutical presently has an average rating of “Moderate Buy” and an average price target of $88.39.

Key Stories Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin reported third-quarter revenue of $1.025 billion, up 32% year over year and in line with estimates. Growth was led by a 44% increase in metabolic-condition revenue and a 12% increase in skeletal-condition revenue. Adjusted earnings of $0.23 per share significantly exceeded consensus expectations for a loss. BioMarin Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: The company added a new investigational Fabry-disease asset to its clinical portfolio, broadening its rare-disease pipeline. Analysts described the recent setback as timing-related and maintained a constructive long-term view; Citi reiterated a Buy rating with projected upside. BioMarin’s Timing-Related Setback Masks Long-Term Growth Potential
• Positive Sentiment: BioMarin said VOXZOGO for hypochondroplasia has a May 30, 2027 PDUFA action date, providing a potential future growth catalyst in skeletal conditions. BioMarin Reports Third Quarter 2026 Financial and Operating Results
• Neutral Sentiment: Several valuation analyses suggested BMRN may be undervalued—one estimated approximately 21% potential upside—although those assessments depend on the company restoring execution and meeting longer-term growth expectations. BioMarin Pharmaceutical Could Be 21% Undervalued
• Negative Sentiment: BioMarin lowered its 2026 guidance, citing uncertainty over order timing and the impact of two acquired in-process research and development charges. Although the quarterly revenue result was on target, the reduced full-year sales outlook is the main reason investors remain cautious. BioMarin Q3 Earnings and Lowered 2026 Guidance

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.